Physician profile
Stephen A Harper
NPI 1710967070
$3,463.17
in general payments reported to CMS, 2019-2025
15 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,563 · 2020: $122 · 2021: $49.78 · 2022: $134 · 2023: $238 · 2024: $197 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,451.49 | 2019-2020 | |
| Genzyme Corporation | $452.09 | 2021-2025 | |
| Stryker Corporation | $109.90 | 2019-2021 | |
| Glaxosmithkline, LLC. | $101.92 | 2023-2025 | Nucala |
| Masimo Corporation | $95.57 | 2022-2025 | Set and Rainbow Set |
| Optinose US, INC. | $79.88 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $46.08 | 2019-2025 | Dupixent |
| Aerin Medical INC. | $28.23 | 2020-2022 | |
| Karl Storz Endoscopy-America | $27.57 | 2019 | |
| Merck Sharp & Dohme LLC | $16.03 | 2025 | Keytruda, Keytruda Qlex |
| Hikma Pharmaceuticals USA | $14.91 | 2025 | Ryaltris |
| Medtronic, INC. | $14.08 | 2025 | Propel |
| Hospira, INC. | $13.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.